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I would like to congratulate Shah and Smith for their excellent comprehensive review of 26 
phenoconversion [1]. They used a narrow definition of personalized medicine restricted to 27 
pharmacogenetics as they described phenoconversion as its Achilles’ heel. A more comprehensive view of 28 
personalized medicine and its application for prescribing medication, personalized prescription, considers 29 
not only genetic factors but environmental and personal factors [2]. Inhibitors, among environmental 30 
factors, and inflammation, among personal factors, can cause phenoconversion to a poor metabolizer (PM) 31 
phenotype.  Personalized prescription can be implemented as personalized drug selection and personalized 32 
dosing [2]. Combining pharmacogenetics and therapeutic drug monitoring (TDM) is the best way for 33 
implementing personalized dosing [3]. Moreover, with TDM, phenoconversion is no longer a problem but a 34 
helpful piece of additional information.       35 
 Venlafaxine and risperidone TDM and CYP2D6 genotyping are described as examples. A plasma 36 
O-desmethylvenlafaxine/venlafaxine concentration ratio <1 signals the absence of CYP2D6 activity,  37 
explained by 1) genetic PM status, or 2) phenoconversion after taking a powerful CYP2D6 inhibitor, or 38 
from competitive inhibition after the use of venlafaxine itself [4]. Shah and Smith described them, 39 
respectively, as gPM and pPM [1]. Preskorn et al. [4], using this ratio, found that venlafaxine had mild 40 
CYP2D6 inhibitory properties and that 21% (159/748) of CYP2D6 extensive metabolizers (EMs) 41 
experienced phenoconversion to pPM status. Not unexpectedly, nine subjects with a genotype of CYP2D6 42 
*4/*10 (a null allele and an allele with very low activity) had a median ratio of 1.2, since venlafaxine 43 
competitively inhibited the very limited CYP2D6 activity they had.                                          44 
  A risperidone TDM ratio was first used in psychiatry to detect phenoconversion during a 45 
risperidone North American randomized clinical trial (RCT) [5]. CYP2D6 EMs had higher plasma 9-46 
hydroxyrisperidone concentrations than risperidone concentrations. If we then calculate a risperidone/9-47 
hydroxyrisperidone ratio for CYP2D6 EMs, the ratio is <1 [6]. An inverted ratio, with higher 48 
concentrations of risperidone than 9-hydroxyrisperidone, occurred in CYP2D6 PMs and was expected in 49 
50% of CYP2D6 EMs taking paroxetine or fluoxetine [5]. Unfortunately, the RCT risperidone TDM data 50 
 3
was never published by the company in a peer-review journal but was only presented in a poster. In a 51 
review article [7], graphics summarized the TDM data from the RCT by focusing on the mean values of the 52 
risperidone/9-hydroxyrisperidone ratio and the total concentration-to-dose ratio (C/D ratio), a measure of 53 
risperidone clearance from the body. The total concentration is calculated by adding the risperidone and 9-54 
hydroxyrisperidone plasma concentrations [7].  55 
In a naturalistic study of risperidone pharmacogenetics, 277 patients provided risperidone TDM 56 
data [8]. Table 1 shows that an inverted ratio (risperidone/9-hydoxirisperidone ratio >1) was present in 57 
almost every CYP2D6 gPM, 95% (19/20) versus 15% (39/257) for the rest of the patients.  58 
Phenoconversion was particularly frequent, 83% (5/6), in the intermediate metabolizers [IMs] taking 59 
CYP2D6 inhibitors. 60 
A clobazam TDM ratio may also be used to establish phenoconversion. After reviewing the 61 
clobazam literature, we have proposed that a steady-state plasma N-desmethylclobazam/clobazam ratio >25 62 
will identify a CYP2C19 gPM as long as CYP2C19 inhibitors are absent [9]. Interpreting clozapine TDM is 63 
more complex, requiring stratification by smoking and gender because they influence CYP1A2 activity. A 64 
clozapine concentration/dose ratio of >1.20 in a US female non-smoker is suggestive of poor clozapine 65 
metabolism [10].       66 
References 67 
1. Shah RR, Smith RL. Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br J 68 
Clin Pharmacol 2015; 79; 222-40. 69 
2. de Leon J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res 70 
2009; 59: 81-9. 71 
3. Crettol S, de Leon J, Hiemke C, Eap CB. Pharmacogenomics in psychiatry: from therapeutic drug 72 
monitoring to genomic medicine. Clin Pharmacol Ther 2014; 95: 254-7. 73 
4. Preskorn SH, Kane CP, Lobello K, Nichols AI, Fayyad R, Buckley G, Focht K, Guico-Pabia CJ. 74 
 4
Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: 75 
implications for personalized medicine. J Clin Psychiatry 2013; 74: 614–21. 76 
5. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin 77 
Psychiatry 1996; 57Suppl 11: 12-25. 78 
6. Bork JA, Rogers T, Wedlund PJ, de Leon J. A pilot study on risperidone metabolism: the role of 79 
cytochromes P450 2D6 and 3A.  J Clin Psychiatry 1999; 60: 469–76. 80 
7. de Leon J, Sandson NB, Cozza KL. A preliminary attempt to personalize risperidone dosing using 81 
drug-drug interactions and genetics: part II. Psychosomatics 2008; 49: 347-61. 82 
8. de Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ. A study of genetic (CYP2D6 and 83 
ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma 84 
risperidone levels. Pharmacopsychiatry 2007;  40: 93-102.  85 
9.  de Leon J, Spina E, Diaz FJ. Clobazam therapeutic drug monitoring: a comprehensive review of the 86 
literature with proposals to improve future studies.  Ther Drug Monit 2013; 35: 30-47. 87 
10. Spina E, de Leon J. Clinical applications of CYP genotyping in psychiatry. J Neural Transm 2015; 88 
122: 5-28.  89 
 90 
 1
Table 1. Frequency of inverted ratios in risperidone TDM study with 277 patients     1 
                            Frequency of inverted ratios1   2 
   Total sample  On inhibitors2  No inhibitors      3 
CYP2D6 genotyping3 4 
gPMs   95% (19/20)  5 
Non gPMs  15% (39/257)4  63% (27/43)4    6% (12/214)4   6 
   gIMs   43% (13/30)4  83%  (5/6)4 33% (8/24)4 7 
   gEMs  12% (26/219)4  61% (22/36)4,5  2% (4/183)4 8 
   gUMs     0%    (0/8)    0%  (0/1)         0%  (0/7)      9 
1Another factor influencing an inverted ratio was body weight. After excluding the CYP2D6 gPMs, a 10 
logistic regression analysis of R/9-OHR >1 was performed. The significant variables were the number of 11 
CYP2D6 active alleles (odds ratio OR=0.18, 99% confidence interval, 0.08, 0.43), use of CYP inhibitors 12 
(OR=16.7; 6.2, 44.9), and body weight higher than the sample mean (OR=0.27, 0.10, 0.69). 13 
2Bupropion, fluoxetine or paroxetine. Bupropion is a moderate CYP2D6 inhibitor; paroxetine and 14 
fluoxetine are potent CYP2D6 inhibitors. 15 
3g refers to genetic. This is the terminology proposed by Shah and Smith [1].  16 
4Any patient who is not a gPM and has an inverted ratio would be a pPM according to the terminology 17 
proposed by Shah and Smith [1].  18 
5Phenoconversion is influenced by CYP2D6 genotype. In the 36 gEMs on inhibitors, the frequency of 19 
inverted ratios was 61%, but the prevalence varied according to the number of active alleles: 80% (12/15) 20 
in those with 1.0 active allele, 71% (5/7) in those with 1.4 active alleles, and 36% (5/14) in those with 2.0 21 
active alleles.     22 
